No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $42 to $33.